Immunohistochemical expression levels of p53 and eIF4E markers in histologically negative surgical margins, and their association with the clinical outcome of patients with head and neck squamous cell carcinoma

Singh,Jagtar; Jayaraj,Rama; Baxi,Siddhartha; Mileva,Mariana; Skinner,John; Dhand,Navneet  K.; Thomas,Mahiban

doi:10.3892/mco.2015.689

Immunohistochemical expression levels of p53 and eIF4E markers in histologically negative surgical margins, and their association with the clinical outcome of patients with head and neck squamous cell carcinoma

Authors:
- Jagtar Singh
- Rama Jayaraj
- Siddhartha Baxi
- Mariana Mileva
- John Skinner
- Navneet K. Dhand
- Mahiban Thomas
View Affiliations

Affiliations: School of Psychological and Clinical Sciences, Charles Darwin University, Darwin, NT 0815, Australia, Genesis Health Care Bunbury, Bunbury, WA 6230, Australia, Department of Anatomical Pathology, Royal Darwin Hospital, Darwin, NT 0810, Australia, Faculty of Veterinary Science, University of Sydney, Camden, NSW 2570, Australia, Department of Head and Neck Surgery, Royal Darwin Hospital, Darwin, NT 0811, Australia
Published online on: December 1, 2015 https://doi.org/10.3892/mco.2015.689
Pages: 166-172

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Molecular markers can be used to identify residual cancer at the surgical margins of head and neck squamous cell carcinoma (HNSCC) and assist in evaluating the complete resection of the tumour. The purpose of the present study was to investigate the expression levels of prognostic molecular markers at the histological tumour free surgical margins. In the present clinical retrospective study, 24/48 patients were selected with negative surgical margins for further analysis with immunohistochemical staining. Contingency tables and Fisher's exact tests were used to investigate the association between the expression levels of p53 and eukaryotic translation imitation factor 4E (eIF4E) with the clinical outcomes for patients with HNSCC. The expression levels of p53 and eIF4E were 54.2 and 87.5%, respectively, in the surgical margins of patients with HNSCC. A total of 3/7 patients with recurrent cancer (42.8%) were identified with p53‑positive margins, and 6 (85.7%) patients exhibited recurrence with eIF4e‑positive margins. No statistically significant differences were identified for the recurrence risk between the overexpression of p53 and eIF4E in the surgical margins (P=0.88 and P=0.99, respectively). The eIF4E marker appears to be a more marked prognosticator compared with p53, as overexpression of eIF4E was identified in the margins of 6/7 patients with local recurrence.

View Figures

View References

1	Rezende TM: deS ouza Freire M and Franco OL: Head and neck cancer: Proteomic advances and biomarker achievements. Cancer. 116:4914–4925. 2010. View Article : Google Scholar : PubMed/NCBI
2	Armstrong W, Vokes DE and Maisel RH: Malignant tumors of the larynx, cummings otolaryngology head & neck surgery (5th). America Mosby Elsevier. 482–511. 2010.
3	Jalali MM, Heidarzadeh A, Zavarei MJ and Sarmast H: p53 overexpression impacts on the prognosis of laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev. 12:1731–1734. 2011.PubMed/NCBI
4	Nathan CO, Franklin S, Abreo FW and Nassar R: DeB enedetti A and Glass J: Analysis of surgical margins with the molecular marker eIF4E: A prognostic factor in patients with head and neck cancer. J Clin Oncol. 17:2909–2914. 1999.PubMed/NCBI
5	Breda A, Konijeti R and Lam JS: Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Rev Anticancer Ther. 7:847–862. 2007. View Article : Google Scholar : PubMed/NCBI
6	Van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW, Snow GB and Brakenhoff RH: Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients, A prospective study. Clin Cancer Res. 10:3614–3620. 2004. View Article : Google Scholar : PubMed/NCBI
7	Nathan CO, Sanders K, Abreo FW, Nassar R and Glass J: Correlation of p53 and the proto-oncogene eIF4E in larynx cancers, Prognostic implications. Cancer Res. 60:3599–3604. 2000.PubMed/NCBI
8	Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D'Silva N, Cordell K, Kleer C, Kupfer R, Kumar P, et al: Biomarkers in advanced larynx cancer. Laryngoscope. 124:179–187. 2014. View Article : Google Scholar : PubMed/NCBI
9	Gasco M and Crook T: The p53 network in head and neck cancer. Oral Oncol. 39:222–231. 2003. View Article : Google Scholar : PubMed/NCBI
10	De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene. 23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
11	Cardesa A and Nadal A: Carcinoma of the head and neck in the HPV era. Acta Dermatovenerol Alp Pannonica Adriat. 20:161–173. 2011.PubMed/NCBI
12	Nathan CO, Liu L, Li B, Abreo FW, Nandy I and De Benedetti A: Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene. 15:579–584. 1997. View Article : Google Scholar : PubMed/NCBI
13	Nathan CO, Amirghahri N, Rice C, Abreo FW, Shi R and Stucker FJ: Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope. 112:2129–2140. 2002. View Article : Google Scholar : PubMed/NCBI
14	Salehi Z and Mashayekhi F: Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem. 39:404–409. 2006. View Article : Google Scholar : PubMed/NCBI
15	Crew JP, Fuggle S, Bicknell R and Cranston DW: deB enedetti A and Harris AL: Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer. 82:161–166. 2000.PubMed/NCBI
16	Liangping X: The prognostic value of pathological and molecular margins marked by p53 and elF4E in laryngeal carcinoma. Chinese-German J Clin Oncol. 4:56–60. 2005.
17	Chakraborty S, Mohiyuddin SM, Gopinath KS and Kumar A: Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer. 8:1632008. View Article : Google Scholar : PubMed/NCBI
18	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
19	Kokko LL, Hurme S, Maula SM, Alanen K, Grénman R, Kinnunen I and Ventelä S: Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 47:510–516. 2011. View Article : Google Scholar : PubMed/NCBI
20	Clark C, Shah S, Herman-Ferdinandez L, Ekshyyan O, Abreo F, Rong X, McLarty J, Lurie A, Milligan EJ and Nathan CO: Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients. Laryngoscope. 120:1159–1165. 2010.PubMed/NCBI
21	Partridge M, Costea DE and Huang X: The changing face of p53 in head and neck cancer. Int J Oral Maxillofac Surg. 36:1123–1138. 2007. View Article : Google Scholar : PubMed/NCBI
22	Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008. View Article : Google Scholar : PubMed/NCBI
23	Chao YK, Chuang WY, Yeh CJ, Chang YS, Wu YC, Kuo SY, Hsieh MJ and Hsueh C: High phosphorylated 4E-binding protein 1 expression after chemoradiotherapy is a predictor for locoregional recurrence and worse survival in esophageal squamous cell carcinoma patients. J Surg Oncol. 105:288–292. 2012. View Article : Google Scholar : PubMed/NCBI
24	Waitzberg AF, Nonogaki S, Nishimoto IN, Kowalski LP, Miguel RE, Brentani RR and Brentani MM: Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas. Cancer Detect Prev. 28:178–186. 2004. View Article : Google Scholar : PubMed/NCBI
25	Song HS, Do YR, Kang SH, Jeong KY and Kim YS: Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer. Cancer Res Treat. 38:218–223. 2006. View Article : Google Scholar : PubMed/NCBI
26	Li S and Wei Q: The expression and the clinical significance of eukaryotic translation initiation factors 4E and p53 in squamous cell carcinoma. Chinese-German J Clin Oncol. 8:286–288. 2009. View Article : Google Scholar
27	Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM and Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53:4477–4480. 1993.PubMed/NCBI
28	Pihan GA, Wallace J, Zhou Y and Doxsey SJ: Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 63:1398–1404. 2003.PubMed/NCBI